PRAX

Praxis Precision Medicines, Inc. NASDAQ

Healthcare ·Biotechnology ·US · praxismedicines.com

$337.61

Mkt Cap $7.1B

52w Low $34.89 94.3% of range 52w High $356.00

50d MA $318.39 200d MA $202.66

P/E (TTM) -24.1x

EV/EBITDA -20.7x

P/B 8.3x

Debt/Equity 0.0x

ROE -34.5%

P/FCF -26.6x

RSI (14) —

ATR (14) —

Beta 2.97

50d MA $318.39

200d MA $202.66

Avg Volume 417.9K

About

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depressi…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
May 4, 2026	BMO	—	—	—	324.20	-0.5%	—	+2.9%	—	—	—	—
Feb 19, 2026	BMO	-3.13	-3.50	-12.0%	328.93	-4.2%	+0.8%	+1.9%	+4.1%	+4.2%	+5.7%	—
Nov 5, 2025	BMO	-3.45	-3.36	+2.6%	171.75	-1.5%	-4.1%	+0.3%	-2.1%	-2.2%	+6.9%	—
Aug 4, 2025	BMO	-3.40	-3.31	+2.6%	54.09	-3.9%	-5.5%	-11.6%	-10.1%	-12.6%	-15.1%	—
May 2, 2025	BMO	-3.20	-3.29	-2.8%	38.06	+1.8%	+5.7%	+2.4%	-7.6%	+0.1%	+0.0%	—
Feb 28, 2025	BMO	-2.76	-2.94	-6.5%	65.03	-38.9%	-40.6%	-48.4%	-44.3%	-41.8%	-41.8%	—
Nov 6, 2024	BMO	-2.01	-2.75	-36.8%	72.73	-2.4%	-1.2%	+3.6%	+7.1%	+16.6%	+14.1%	—
Aug 13, 2024	BMO	-2.38	-1.74	+26.9%	51.82	-4.3%	+0.8%	-1.1%	+5.2%	+2.0%	+0.0%	—
May 13, 2024	BMO	-2.01	-2.84	-41.3%	48.78	-3.4%	-7.4%	-5.9%	-9.8%	-7.3%	-6.9%	—
Mar 5, 2024	BMO	-3.15	-2.97	+5.7%	54.71	+2.4%	-1.9%	+6.3%	+3.1%	+2.3%	-3.0%	—
Nov 7, 2023	BMO	-5.25	-2.70	+48.6%	14.79	+8.5%	+6.5%	+1.4%	-0.5%	-0.6%	-11.8%	—
Aug 9, 2023	BMO	-9.90	-7.35	+25.8%	14.49	-1.7%	+0.4%	+10.8%	+13.9%	+17.0%	+15.9%	—
May 11, 2023	BMO	-11.24	-10.64	+5.3%	16.05	+1.9%	+0.0%	-2.8%	+0.9%	-1.9%	-0.9%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Apr 14	Needham	Maintains	Buy → Buy	—	$317.00	$325.95	+2.8%	+8.4%	+7.2%	+1.1%	+8.0%	+8.1%
Apr 7	HC Wainwright & Co.	Maintains	Buy → Buy	—	$310.11	$309.41	-0.2%	-1.1%	+3.3%	+3.3%	+1.9%	+2.2%
Apr 6	BTIG	Maintains	Buy → Buy	—	$310.38	$318.76	+2.7%	-0.1%	-1.2%	+3.2%	+3.2%	+1.9%
Feb 20	Baird	Maintains	Outperform → Outperform	—	$331.61	$332.52	+0.3%	+1.1%	+3.3%	+3.3%	+4.8%	+2.7%
Feb 20	Wells Fargo	Maintains	Equal Weight → Equal Weight	—	$331.61	$332.52	+0.3%	+1.1%	+3.3%	+3.3%	+4.8%	+2.7%
Feb 20	Wedbush	Maintains	Underperform → Underperform	—	$331.61	$332.52	+0.3%	+1.1%	+3.3%	+3.3%	+4.8%	+2.7%
Feb 20	Truist	Maintains	Buy → Buy	—	$331.61	$332.52	+0.3%	+1.1%	+3.3%	+3.3%	+4.8%	+2.7%
Feb 10	Guggenheim	Maintains	Buy → Buy	—	$319.54	$325.40	+1.8%	+0.3%	+1.2%	+4.2%	-0.7%	+2.7%
Feb 4	Needham	Maintains	Buy → Buy	—	$310.52	$311.75	+0.4%	-2.3%	-1.6%	+2.9%	+2.9%	+3.2%
Jan 30	HC Wainwright & Co.	Maintains	Buy → Buy	—	$314.28	$315.00	+0.2%	-0.1%	-1.6%	-1.2%	-3.5%	-2.8%
Jan 28	Piper Sandler	Maintains	Overweight → Overweight	—	$314.75	$323.00	+2.6%	-1.5%	-0.1%	-0.2%	-1.8%	-1.3%
Jan 12	Wedbush	Maintains	Underperform → Underperform	—	$288.45	$283.00	-1.9%	-4.4%	-2.6%	+3.5%	+3.2%	+10.0%
Dec 29	BTIG	Maintains	Buy → Buy	—	$268.95	$317.72	+18.1%	+13.2%	+10.4%	+9.6%	+6.5%	+3.0%
Dec 15	Oppenheimer	Maintains	Outperform → Outperform	—	$268.80	$272.46	+1.4%	+2.8%	+2.1%	-1.1%	+0.2%	+1.5%
Dec 9	Jefferies	Maintains	Buy → Buy	—	$270.98	$271.00	+0.0%	-4.7%	-3.5%	-1.4%	-0.8%	+2.0%
Dec 9	Guggenheim	Maintains	Buy → Buy	—	$270.98	$271.00	+0.0%	-4.7%	-3.5%	-1.4%	-0.8%	+2.0%
Dec 8	BTIG	Maintains	Buy → Buy	—	$247.99	$256.92	+3.6%	+9.3%	+4.1%	+5.5%	+7.8%	+8.4%
Dec 8	Truist	Maintains	Buy → Buy	—	$247.99	$256.92	+3.6%	+9.3%	+4.1%	+5.5%	+7.8%	+8.4%
Dec 8	TD Cowen	Maintains	Buy → Buy	—	$247.99	$256.92	+3.6%	+9.3%	+4.1%	+5.5%	+7.8%	+8.4%
Dec 8	HC Wainwright & Co.	Maintains	Buy → Buy	—	$247.99	$256.92	+3.6%	+9.3%	+4.1%	+5.5%	+7.8%	+8.4%
Dec 8	Needham	Maintains	Buy → Buy	—	$247.99	$256.92	+3.6%	+9.3%	+4.1%	+5.5%	+7.8%	+8.4%
Dec 5	Wedbush	Maintains	Underperform → Underperform	—	$189.97	$241.00	+26.9%	+30.5%	+42.6%	+35.9%	+37.7%	+40.7%
Dec 5	HC Wainwright & Co.	Maintains	Buy → Buy	—	$189.97	$241.00	+26.9%	+30.5%	+42.6%	+35.9%	+37.7%	+40.7%
Dec 5	Needham	Maintains	Buy → Buy	—	$189.97	$241.00	+26.9%	+30.5%	+42.6%	+35.9%	+37.7%	+40.7%
Dec 1	Needham	Maintains	Buy → Buy	—	$196.46	$193.44	-1.5%	-6.1%	-8.8%	-5.2%	-3.3%	+26.2%
Nov 25	HC Wainwright & Co.	Maintains	Buy → Buy	—	$190.86	$191.59	+0.4%	-3.5%	-1.2%	+2.9%	-3.3%	-6.2%
Nov 13	HC Wainwright & Co.	Maintains	Buy → Buy	—	$183.61	$184.15	+0.3%	-3.0%	+1.5%	+7.6%	+0.3%	+3.1%
Nov 6	Wedbush	Maintains	Underperform → Underperform	—	$164.64	$164.01	-0.4%	+4.7%	+2.2%	+2.0%	+11.5%	+11.5%
Oct 20	Wedbush	Maintains	Underperform → Underperform	—	$189.99	$190.00	+0.0%	-7.9%	+0.0%	-2.9%	-6.3%	-8.4%
Oct 17	Deutsche Bank	Maintains	Buy → Buy	—	$162.71	$178.90	+10.0%	+16.8%	+7.6%	+16.8%	+13.3%	+9.4%
Oct 17	Guggenheim	Maintains	Buy → Buy	—	$162.71	$178.90	+10.0%	+16.8%	+7.6%	+16.8%	+13.3%	+9.4%
Oct 17	Chardan Capital	Maintains	Buy → Buy	—	$162.71	$178.90	+10.0%	+16.8%	+7.6%	+16.8%	+13.3%	+9.4%
Oct 17	Truist	Maintains	Buy → Buy	—	$162.71	$178.90	+10.0%	+16.8%	+7.6%	+16.8%	+13.3%	+9.4%
Oct 16	Jefferies	Maintains	Buy → Buy	—	$57.35	$158.29	+176.0%	+183.7%	+231.3%	+205.3%	+231.3%	+221.6%
Oct 16	Needham	Maintains	Buy → Buy	—	$57.35	$158.29	+176.0%	+183.7%	+231.3%	+205.3%	+231.3%	+221.6%
Oct 16	HC Wainwright & Co.	Maintains	Buy → Buy	—	$57.35	$158.29	+176.0%	+183.7%	+231.3%	+205.3%	+231.3%	+221.6%
Aug 5	HC Wainwright & Co.	Maintains	Buy → Buy	—	$51.09	$53.05	+3.8%	-6.5%	-4.9%	-7.5%	-10.1%	-12.0%
Jul 29	Chardan Capital	Maintains	Buy → Buy	—	$55.65	$57.72	+3.7%	+0.6%	+1.7%	-2.6%	-2.8%	-8.2%
Jul 18	HC Wainwright & Co.	Maintains	Buy → Buy	—	$54.94	$55.53	+1.1%	-2.0%	+0.4%	+0.9%	+3.9%	+5.6%
Jul 8	Oppenheimer	Maintains	Outperform → Outperform	—	$46.68	$47.37	+1.5%	+0.2%	+7.5%	+7.8%	+8.3%	+14.8%
Jun 12	Needham	Maintains	Buy → Buy	—	$44.60	$44.01	-1.3%	+1.0%	-0.7%	-1.8%	-2.6%	-3.7%
May 5	Needham	Maintains	Buy → Buy	—	$40.24	$40.89	+1.6%	-3.2%	-12.6%	-5.3%	-5.4%	-4.7%
May 5	Wedbush	Maintains	Underperform → Underperform	—	$40.24	$40.89	+1.6%	-3.2%	-12.6%	-5.3%	-5.4%	-4.7%
May 1	HC Wainwright & Co.	Maintains	Buy → Buy	—	$37.64	$37.44	-0.5%	+1.1%	+6.9%	+3.5%	-6.6%	+1.2%
Apr 8	Needham	Maintains	Buy → Buy	—	$31.53	$33.99	+7.8%	-9.3%	-2.2%	-9.7%	-5.7%	-5.6%
Mar 3	Baird	Maintains	Outperform → Outperform	—	$38.60	$38.61	+0.0%	-13.1%	-6.2%	-1.9%	-1.9%	-0.3%
Mar 3	Truist	Maintains	Buy → Buy	—	$38.60	$38.61	+0.0%	-13.1%	-6.2%	-1.9%	-1.9%	-0.3%
Mar 3	HC Wainwright & Co.	Maintains	Buy → Buy	—	$38.60	$38.61	+0.0%	-13.1%	-6.2%	-1.9%	-1.9%	-0.3%
Mar 3	Needham	Maintains	Buy → Buy	—	$38.60	$38.61	+0.0%	-13.1%	-6.2%	-1.9%	-1.9%	-0.3%
Feb 10	Needham	Maintains	Buy → Buy	—	$86.88	$88.75	+2.2%	-2.3%	-3.0%	-1.7%	-0.3%	+4.5%

Recent Filings

8-K · 8.01 !! High

Unknown — 8-K 8.01: Material Event / Announcement

This 8-K filing lacks substantive disclosure details, making it impossible to assess material impact; investors should review the actual filing or company announcements for clarity on what event triggered this report.

Apr 14

8-K · 8.01 !! High

Unknown — 8-K 8.01: Material Event / Announcement

FDA priority review of relutrigine for rare genetic epilepsies suggests accelerated approval timeline, potentially creating near-term catalyst that could drive PRAX stock higher if development progresses successfully.

Apr 6

8-K

Praxis Precision Medicines, Inc. -- 8-K Filing

Praxis Precision Medicines advanced its pipeline with two FDA drug applications for ulixacaltamide and relutrigine, positioning the company for potential near-term approvals and 2026 commercialization launches in neurology markets.

Feb 19

8-K · 5.02 !!! Very High

Praxis Precision Medicines, Inc. -- 8-K 5.02: Executive Change

Praxis Precision Medicines adds Jeffrey B. Kindler to its board of directors, effective January 8, 2026, potentially bringing additional oversight and strategic guidance to the clinical-stage pharmaceutical company.

Feb 10

Data updated apr 26, 2026 8:34pm · Source: massive.com